Open Study of the Duration of Immunity After Vaccination With GamEvac

Hemorrhagic Fever, Ebola Clinical Trial

Official title:

Open Study of the Duration of Immunity After Vaccination With Medicinal Product GamEvac-Vector-Based Vaccine Against Ebola Virus Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02911428
• Other study ID #: 03 - GamEvac-2016
• Status: Completed
• Phase: N/A
• First received: September 14, 2016
• Last updated: December 25, 2017
• Start date: October 2016
• Est. completion date: December 25, 2017

Study information

• Verified date: September 2016
• Source: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety of medicinal product GamEvacVector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose, following the immunization with a half (0.25 ml+0.25 ml/dose) and full (0.5 ml+0.5 ml/dose) therapeutic doses.

Description:

This clinical trial is designed as an open study to evaluate the duration of immunity persistence following the administration of medicinal product GamEvac Vector-Based Vaccine against Ebola Virus Disease.

It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure specified in this Protocol. Only those patients who have signed the information consent form for participation in the study and have been informed by physician on the objectives and methods of this project will be involved in the study.

The study consists of a single stage which is designed as a follow-up period to observe volunteers vaccinated in the course of evaluation of safety, reactogenic properties and immunogenicity of product GamEvac Vector-Based Vaccine against Ebola Virus Disease in the dosages of 0.25 ml and 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015. Vaccination will not be made within the present study. Screening of volunteers is not required: the study will involve as many of the volunteers as possible (but not more than 60 subjects) who had been immunized earlier with GamEvac Vector-Based Vaccine against Ebola Virus Disease, provided that they have no medical contraindications for blood sampling.

Study Schedule Visit 1 (outpatient): the goal of this visit is to assess whether a patient meets the inclusion/exclusion criteria. All procedures should be carried out upon receipt of the informed consent form signed by patient. The visit will be held 12 months after the vaccination.

Visit 2 (outpatient): 18 months after the vaccination. Visit 3 (outpatient): 24 months after the vaccination. The duration of immunity persistence following product administration will be assessed in healthy volunteers based on the measurements of specific antibody titers.

by ELISA method 12, 18 and 24 months after the vaccination vs. baseline values; in virus neutralization reaction 12 months after the vaccination vs. baseline values.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 25, 2017
• Est. primary completion date: December 25, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 56 Years

Eligibility

Inclusion Criteria:

• Males and females aged 18-56 who had been earlier vaccinated with medicinal product GamEvac in the dosages of 0.25 ml and 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.

• Written informed consent signed by patients prior to their involvement in the study

Exclusion Criteria:

• Absence of the earlier vaccination with medicinal product GamEvac in the dosages of 0.25 ml and 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.

• Presence of a concomitant illness which could preclude obtaining a venous blood sample or affect the study process: (critical patient's condition, seizures, agitated state, blood loss and shocks of different origin).

Related Conditions & MeSH terms

• Hemorrhagic Fever, Ebola

Intervention

Procedure:
• blood sampling collection
It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.

Locations

Country	Name	City	State
Russian Federation	Federal state budget military educational institution of higher education "Military medical Academy named after S. M. Kirov" Ministry of defense of the Russian Federation	Saint Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	duration of immunity using ELISA method	To evaluate the duration of immunity persistence following the product administration in healthy volunteers by measuring the specific antibody titer: - using ELISA method 12 months after the vaccination vs. baseline values	12 months after the vaccination
Primary	duration of immunity using ELISA method	To evaluate the duration of immunity persistence following the product administration in healthy volunteers by measuring the specific antibody titer: - using ELISA method 18 months after the vaccination vs. baseline values	18 months after the vaccination
Primary	duration of immunity using ELISA method	To evaluate the duration of immunity persistence following the product administration in healthy volunteers by measuring the specific antibody titer: - using ELISA method 24 months after the vaccination vs. baseline values	24 months after the vaccination
Secondary	duration of immunity in virus neutralization reaction	To evaluate the duration of immunity persistence following the product administration in healthy volunteers by measuring the specific antibody titer	12 months after the vaccination vs. baseline values
Secondary	Incidence of Treatment-Emergent Adverse Events	Incidence of Treatment-Emergent Adverse Events. To assess product safety by collecting information on adverse events, development of infectious and non-infectious diseases, and on cases where vaccinated volunteers were seeking for medical care during the follow-up period	12, 18 and 24 months after the vaccination